|
|
发表于 19-11-2009 12:35 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 19-11-2009 08:34 AM
|
显示全部楼层
回复 121# 葉芬 的帖子
休息是为了走更长远的路 
PARD  以为它是另一个NLST |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 19-11-2009 08:36 AM
|
显示全部楼层
Year to Date 2009 Largest Biggest Percentage Gainers or Winners. Top Penny Stocks trading under $2.00 with volume.
As of 11/19/09 9:30am EST
#1 CTIC $1.13 +707.14%
#2 TSEM $1.01 +621.43%
#3 ENMD $1.13 +606.25%
#4 SBSA $0.70 +600.00%
#5 ASTC $1.76 +576.92%
#6 WAVE $0.60 +564.44%
#7 ZHNE $0.50 +525.00%
#8 ADAT $1.43 +450.00%
#9 SIRI $0.64 +431.67%
#10 ANPI $1.31 +403.85%
#11 LTXC $1.35 +400.00%
#12 NAVI $1.99 +397.50%
#13 BGP $1.95 +387.50%
#14 CVM $1.35 +362.07%
#15 CHCI $0.78 +358.82% |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 19-11-2009 08:37 AM
|
显示全部楼层
Economic Calendar Data - 11/19/09
Initial Jobless Claims - Last Week - 8:30am EST - expected 498,000
Philadelphia Fed - November 2009 - 10am EST - expected 12.50 |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 19-11-2009 08:38 AM
|
显示全部楼层
Top Stocks to Watch - 11/19/09
DayStar Technologies Inc. (DSTI)
Ambac Financial Group, Inc. (ABK) (今晚应该还有看头)
La-Z-Boy Inc. (LZB)
LDK Solar Co.Ltd. (LDK)
Netlist Inc. (NLST)
[ 本帖最后由 roberto 于 19-11-2009 08:51 AM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:28 AM
|
显示全部楼层
再來一次。。 
19/11/09
Netlist Inc. (NLST) - NLST soared Wednesday on no news. This stock continues to offer incredible trading opportunities for the active day trader. Support is located at $4.60, $4.20, and $4.00. Support is located between $4.60-$4.70 while resistance is at $5.39 & $6.09. |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:30 AM
|
显示全部楼层
Miku 昨晚你有買進嗎？
19/11/09
Ambac Financial Group, Inc. (ABK) - Ambac capital exceeds required minimum; shares up. Resistance on ABK is located at $1.03 as well as $1.13. |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:00 PM
|
显示全部楼层
PARD - 100% 短/中/長期 都是 Buy 哦
Date Open High Low Last Change Volume % Change
11/18/09 2.72 2.80 2.31 2.38 -0.10 19359000 -4.03%
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Buy
Short Term Indicators Average: 100% - Buy
20-Day Average Volume - 8103535
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 5002726
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 3516251
Overall Average: 100% - Buy
Price Support Pivot Point Resistance
2.38 2.01 2.50 2.99 |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:02 PM
|
显示全部楼层
NLST 也是 96% BUY 哦
Date Open High Low Last Change Volume % Change
11/18/09 4.22 5.39 4.22 4.83 +0.73 12550600 +17.80%
Composite Indicator
Trend Spotter TM Buy
Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold
Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 3414045
Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 1394718
Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 746382
Overall Average: 96% - Buy
Price Support Pivot Point Resistance
4.83 3.64 4.81 5.98 |
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 19-11-2009 09:05 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:07 PM
|
显示全部楼层
原帖由 roberto 于 19-11-2009 09:05 PM 发表 
对咯, 葉姐怎么看?
要看今晚的Market怎樣。。。。
目前Future 不大好看。。。
| YMZ09.CBT | Mini Dow Jones Indus.-$5 Dec 09 | 10,344.00 7:56am ET |  60.00 (0.58%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:28 PM
|
显示全部楼层
|
aig好奇怪，昨天排卖36.74.。。她起到36.75，不过我没卖到？？奇怪 |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:37 PM
|
显示全部楼层
原帖由 miku 于 19-11-2009 09:28 PM 发表
aig好奇怪，昨天排卖36.74.。。她起到36.75，不过我没卖到？？奇怪
可以和你的Remisier 查看下，那36.75的是那個Exchange 做到。。
為何你的36.74的沒做到。。。他們查的到。 |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:42 PM
|
显示全部楼层
应该是我limit他一定要36.74卖，所以没做到。
今晚投机pard |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:43 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:46 PM
|
显示全部楼层
这里有人申请 Singapore CapitalMall Asias 的IPO吗？
Note:有点离题哦 |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 09:52 PM
|
显示全部楼层
原帖由 miku 于 19-11-2009 09:43 PM 发表
不过那天做莫从7.xx掉到2.xx？？
她的Clinical data Result 不好。。
所以股價往下跌。。。
最新的1小時前。。。
PoniardPharmaceuticals Announces Updated Positive Clinical Data From Phase 2Trial Of Picoplatin In Colorectal Cancer And New Phase 1 Cardiac SafetyTrial Results November 19, 2009
- Data Presented at AACR-NCI-EORTC's "Molecular Targets and Cancer Therapeutics" International Conference -South San Francisco, CA./PRNewswire-FirstCall/ - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD)today announced updated clinical data from its randomized, controlledPhase 2 trial of picoplatin in patients with metastatic colorectalcancer (CRC). The updated results indicated that picoplatin, given onceevery four weeks in combination with 5-fluorouracil and leucovorin inthe FOLPI regimen, has comparable efficacy to oxaliplatin, given incombination with 5-fluorouracil and leucovorin in the modified FOLFOX-6regimen, as a first-line therapy for CRC, as assessed by one-yearsurvival rate, progression-free survival (PFS) and disease control. TheCompany also announced new results from its Phase 1 cardiac safetytrial, which showed no clinical cardiac-related events, as expected.
New data for both clinical trials were presented today inposter sessions during the AACR-NCI-EORTC's "Molecular Targets andCancer Therapeutics" International Conference in Boston. Picoplatin isa new generation platinum-based chemotherapy agent and the Company'slead product candidate in development.
"Our updated proof-of-concept Phase 2 safety and efficacyresults continue to suggest that picoplatin could be superior tooxaliplatin as a neuropathy-sparing alternative when used incombination as a first-line treatment for metastatic colorectal cancer.We are continuing follow-up on patients to obtain median overallsurvival data to facilitate an end of Phase 2 meeting with the U.S.Food and Drug Administration," said Jerry McMahon, Ph.D., chairman andCEO of Poniard. "Based on the current data in colorectal cancer, aswell as encouraging efficacy and safety data from more than 1,100cancer patients treated with picoplatin in clinical trials, includingthe cardiac safety trial data presented today, we are continuingdiscussions with potential partners."
Phase 2 CRC Trial Design and Results
The randomized,controlled Phase 2 trial is evaluating picoplatin as aneuropathy-sparing alternative to oxaliplatin for the first-linetreatment of metastatic CRC in 101 patients who have not received priorchemotherapy. The trial is comparing the safety and efficacy (assessedby objective tumor response, PFS and overall survival) of intravenouspicoplatin given once every four weeks in combination with bi-weekly5-fluorouracil and leucovorin (the FOLPI regimen) with oxaliplatingiven in combination with 5-fluorouracil and leucovorin in themFOLFOX-6 regimen.
The new data presented at the AACR-NCI-EORTC Conferencecontinued to demonstrate comparable efficacy between the two arms. Themedian PFS was 6.8 months for FOLPI-treated patients and 7.0 months formFOLFOX-6-treated patients.
Disease control rates (complete response plus partial responseplus stable disease rates) were also comparable between the twotreatment groups with 75 percent of FOLPI-treated patients and 76percent of mFOLFOX-6-treated patients experiencing disease control. Todate, the one-year survival rate is 52 percent for patients treatedwith FOLPI and 55 percent for patients treated with mFOLFOX-6.
With regard to safety, three separate assessments of neuropathyshowed that the use of FOLPI was associated with significantly lessneurotoxicity than mFOLFOX-6 (p<0.0019). Neuropathy occurred laterand was less frequent and less severe with FOLPI. Most patients whodecided to discontinue FOLFOX because of adverse effects did so becauseof a Grade 1-3 neuropathy (7 patients on FOLFOX verses no patients onFOLPI). Updated patient data demonstrated that FOLPI was associatedwith more frequent and severe, but manageable, neutropenia andthrombocytopenia that resulted in a low frequency of clinicalcomplications and growth factor use for bone marrow suppression. Mostother toxicities, including gastrointestinal toxicity, were shown to besimilar in frequency between the two treatment groups.
Cardiac Safety Study Design and Results
Poniardworked collaboratively with the U.S. Food and Drug Administration (FDA)to design the Phase 1 cardiac safety study, which is required for newchemical entities. The study evaluated the cardiac safety of picoplatinby determining its effect on the cardiac QT/QTc interval by usingtime-matched pharmacokinetics and electrocardiograms (ECGs). A total of45 patients with advanced solid malignancies received 150 mg/m2picoplatin. The trial was conducted at seven clinical sites in theUnited States. Final results of the study presented at theAACR-NCI-EORTC Conference showed that picoplatin had no effect on theQTcF interval or any other ECG parameters evaluated. These findingssupport the clinical data showing that picoplatin does not increase therisk of serious ventricular arrhythmias. In addition, although thestudy was not designed to evaluate efficacy, of the 45 cancer patientsevaluated, 11 had stable disease and two had a partial response,including a patient who is still undergoing treatment after more thanseven months of picoplatin therapy.
[ 本帖最后由 葉芬 于 19-11-2009 09:53 PM 编辑 ] |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 10:07 PM
|
显示全部楼层
人家就是懒得看英语 以为你会解释。。。
还是要自己看。好的。跌破2我买 |
|
|
|
|
|
|
|
|
|
|
|
发表于 19-11-2009 10:25 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
楼主 |
发表于 19-11-2009 11:27 PM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
2355 
32
